Status:
RECRUITING
Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Atrial Fibrillation
Ventricular Tachycardia
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this observational study is to determine if electrophysiologic mapping and cardiac MRI can help identify patients that have genetic forms of cardiomyopathy that are at high risk for develo...
Detailed Description
New genomic knowledge is poised to change clinical practice for atrial fibrillation (AF). In 1293 cases previously considered idiopathic, the investigators identified a pathogenic variant in a cardiom...
Eligibility Criteria
Inclusion
- Adults aged 18 and older
- Diagnosed with AF, frequent PVCs, or VT before age 60
- Scheduled for catheter-based AF ablation (de-novo or repeat) OR catheter-based PVC ablation OR catheter-based VT ablation
- Able to provide written, informed consent
- P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.
Exclusion
- Diagnosed with a genetic CM or arrhythmia syndrome prior to ablation procedure
- VUS in 'possibly pathogenic' subgroup (control group only)
- Previous PVC or VT ablation
- LVEF \<20%
- Prosthetic mitral or aortic valve
- Contraindication to heparin
- Prior myocardial infarction
Key Trial Info
Start Date :
December 13 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2029
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06575881
Start Date
December 13 2023
End Date
December 1 2029
Last Update
September 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232